Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70150 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Takanori Ito und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Nagoya University Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Grants-in-Aid for Scientific Research, Research from the National Center for Global Health and Medicine.
Abstract (Originalsprache)
Background and Aim Data on sequential immune checkpoint inhibitor (ICI) retreatment following initial atezolizumab plus bevacizumab (Atez + Bev) are limited. This study aimed to evaluate the efficacy and safety of sequential ICI retreatment in patients with unresectable hepatocellular carcinoma (uHCC).
Methods
Of 835 patients with uHCC treated with Atez + Bev, 75 who underwent ICI retreatment after initial Atez + Bev therapy were included in this multicenter retrospective study that assessed the efficacy and safety of ICIs.
Results
The participants received one of three sequential retreatments with ICI regimens: durvalumab plus tremelimumab ( n = 58), retreatment with Atez + Bev ( n = 15), and durvalumab monotherapy ( n = 2). The objective response rates (ORRs)/disease control rates (DCRs) for the initial Atez + Bev and sequential ICI retreatment were 34.7%/89.3% and 18.7%/54.7%, respectively. No significant differences in antitumor response were observed among the three ICI retreatment regimens. Patients who achieved a good antitumor response (≥ stable disease) following retreatment showed a significantly longer overall survival. Multivariate analysis identified prior objective response to Atez + Bev as an independent predictor of disease control after retreatment (odds ratio: 3.79, p = 0.016). Immune‐related adverse events (irAEs) requiring corticosteroids occurred in 26.7% of the patients during ICI retreatment, with enterocolitis and rash being the most common. The recurrence rate of irAEs was 15.4% in patients with previous steroid‐requiring irAEs.
Conclusions
Sequential ICI retreatment may be a viable therapeutic option for selected patients with uHCC, particularly those with a favorable response to prior Atez + Bev. Although less effective than first‐line therapy, careful patient selection and monitoring ensure efficacy with acceptable safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Nagoya University Hospital, Nagoya, Japan.
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
- Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
- Department of Gastroenterology, Okayama University Hospital, Okayama, Japan.
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, Japan.
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
ORCID-Profile: Shigeo Shimose, Tetsu Tomonari, Ryu Sasaki, Satoru Kakizaki, Takeshi Hatanaka, Hideki Iwamoto, Takafumi Yamamoto, Hisamitsu Miyaaki, Taro Takami, Takumi Kawaguchi, Hiroki Kawashima
Förderung
- Grants-in-Aid for Scientific Research
- Research from the National Center for Global Health and Medicine
Zitieren
APA
Ito, T., Shimose, S., Saeki, I., Takeuchi, Y., Tani, J., Tomonari, T., Sasaki, R., Sasaki, K., Kakizaki, S., Hatanaka, T., Iwamoto, H., Tanabe, N., Yamamoto, T., Naganuma, A., Shirono, T., Kanayama, Y., Miyaaki, H., Nishina, S., Takayama, T., …, & Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group (2026). Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70150
Vancouver
Ito T, Shimose S, Saeki I, Takeuchi Y, Tani J, Tomonari T, et al. Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70150
BibTeX
@article{Ito2026,
author = {Ito, Takanori and Shimose, Shigeo and Saeki, Issei and Takeuchi, Yasuto and Tani, Joji and Tomonari, Tetsu and Sasaki, Ryu and Sasaki, Kyo and Kakizaki, Satoru and Hatanaka, Takeshi and Iwamoto, Hideki and Tanabe, Norikazu and Yamamoto, Takafumi and Naganuma, Atsushi and Shirono, Tomotake and Kanayama, Yuki and Miyaaki, Hisamitsu and Nishina, Sohji and Takayama, Tetsuji and Kobara, Hideki and Otsuka, Motoyuki and Takami, Taro and Kawaguchi, Takumi and Kawashima, Hiroki and Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group},
title = {Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70150}
}
EUVIMED